Oracle Investment Management’s Day One Biopharmaceuticals DAWN Stock Holding History

Oracle Investment Management’s Portfolio DAWN Stock Details DAWN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$932K	Buy	+100,000	New	+$835K	0.56%	15

Other funds holding DAWN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Oracle Investment Management's DAWN Position: Q4 2025 in Review

Oracle Investment Management opened a new position in Day One Biopharmaceuticals (DAWN) in Q4 2025: 100,000 shares worth $932K. The stake represents 0.56% of the portfolio and ranks #15 among its holdings.

183 funds tracked by Wall St. Rank hold DAWN as of Q4 2025.

Oracle Investment Management held 100,000 shares of Day One Biopharmaceuticals worth $932K as of Q4 2025.
Day One Biopharmaceuticals was a new Oracle Investment Management position in Q4 2025.
Day One Biopharmaceuticals made up 0.56% of Oracle Investment Management's portfolio in Q4 2025, its #15 holding.
183 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q4 2025.

Based on Oracle Investment Management's 13F filing for Q4 2025, filed 18 Feb 2026.